|
1
|
Hoy SM: Dinutuximab: A review in high-risk
neuroblastoma. Target Oncol. 11:247–253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brodeur GM: Neuroblastoma: Biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sano H, Bonadio J, Gerbing RB, London WB,
Matthay KK, Lukens JN and Shimada H: International neuroblastoma
pathology classification adds independent prognostic information
beyond the prognostic contribution of age. Eur J Cancer.
42:1113–1119. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kraal K, Blom T, Tytgat L, van Santen H,
van Noesel M, Smets A, Bramer J, Caron H, Kremer L and van der Pal
H: Neuroblastoma with intraspinal extension: Health problems in
long-tterm survivors. Pediatr Blood Cancer. 63:990–996. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gigliotti AR, de Ioris MA, de Grandis E,
Podda M, Cellini M, Sorrentino S, de Bernardi B, Paladini D and
Gandolfo C: Congenital neuroblastoma with symptoms of epidural
compression at birth. Pediatr Hematol Oncol. 33:94–101. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yokoyama H, Sawada J, Katoh S, Matsuno K,
Ogo N, Ishikawa Y, Hashimoto H, Fujii S and Asai A: Structural
basis of new allosteric inhibition in kinesin spindle protein Eg5.
ACS Chem Boil. 10:1128–1136. 2015. View Article : Google Scholar
|
|
7
|
El-Nassan HB: Advances in the discovery of
kinesin spindle protein (Eg5) inhibitors as antitumor agents. Eur J
Med Chem. 62:614–631. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wakui H, Yamamoto N, Nakamichi S, Tamura
Y, Nokihara H, Yamada Y and Tamura T: Phase 1 and dose-finding
study of patritumab (U3-1287), a human monoclonal antibody
targeting HER3, in Japanese patients with advanced solid tumors.
Cancer Chemother Pharmacol. 73:511–516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gerecitano JF, Stephenson JJ, Lewis NL,
Osmukhina A, Li J, Wu K, You Z, Huszar D, Skolnik JM and Schwartz
GK: A Phase I trial of the kinesin spindle protein (Eg5) inhibitor
AZD4877 in patients with solid and lymphoid malignancies. Invest
New Drugs. 31:355–362. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hollebecque A, Deutsch E, Massard C,
Gomez-Roca C, Bahleda R, Ribrag V, Bourgier C, Lazar V, Lacroix L,
Gazzah A, et al: A phase I, dose-escalation study of the
Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or
lymphoma. Invest New Drugs. 31:1530–1538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishikawa K, Tohyama K, Mitsuhashi S and
Maruta S: Photocontrol of the mitotic kinesin Eg5 using a novel
S-trityl-l-cysteine analogue as a photochromic inhibitor. J
Biochem. 155:257–263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaan HY, Weiss J, Menger D, Ulaganathan V,
Tkocz K, Laggner C, Popowycz F, Joseph B and Kozielski F:
Structure-activity relationship and multidrug resistance study of
new S-trityl-L-cysteine derivatives as inhibitors of Eg5. J Med
Chem. 54:1576–1586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ishikawa K, Tamura Y and Maruta S:
Photocontrol of mitotic kinesin Eg5 facilitated by thiol-reactive
photochromic molecules incorporated into the loop L5 functional
loop. J Biochem. 155:195–206. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun D, Lu J, Ding K, Bi D, Niu Z, Cao Q,
Zhang J and Ding S: The expression of Eg5 predicts a poor outcome
for patients with renal cell carcinoma. Med Oncol. 30:4762013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Muretta JM, Jun Y, Gross SP, Major J,
Thomas DD and Rosenfeld SS: The structural kinetics of switch-1 and
the neck linker explain the functions of kinesin-1 and Eg5. Proc
Natl Acad Sci USA. 112:E6606–E6613. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ngan ES: Heterogeneity of neuroblastoma.
Oncoscience. 2:837–838. 2015.PubMed/NCBI
|
|
17
|
Mei H, Lin ZY and Tong QS: Risk
stratification and therapeutics of neuroblastoma: The challenges
remain. World J Pediatr. 12:5–7. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alderton GK: Neuroblastoma: Enhancing
risk. Nat Rev Cancer. 16:52016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Exertier P, Javerzat S, Wang B, Franco M,
Herbert J, Platonova N, Winandy M, Pujol N, Nivelles O, Ormenese S,
et al: Impaired angiogenesis and tumor development by inhibition of
the mitotic kinesinEg5. Oncotarget. 4:2302–2316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Salmela AL and Kallio MJ: Mitosis as an
anti-cancer drug target. Chromosoma. 122:431–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun L, Lu J, Niu Z, Ding K, Bi D, Liu S,
Li J, Wu F, Zhang H, Zhao Z and Ding S: A potent chemotherapeutic
strategy with Eg5 inhibitor against gemcitabine resistant bladder
cancer. PLoS One. 10:e01444842015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Good JA, Wang F, Rath O, Kaan HY,
Talapatra SK, Podgórski D, MacKay SP and Kozielski F: Optimized
S-trityl-L-cysteine-based inhibitors of kinesin spindle protein
with potent in vivo antitumor activity in lung cancer
xenograftmodels. J Med Chem. 56:1878–1893. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu G, Xu Z and Hao D: MicroRNA-451
inhibits neuroblastoma proliferation, invasion and migration by
targeting macrophage migration inhibitory factor. Mol Med Rep.
13:2253–2260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stafman LL and Beierle EA: Cell
proliferation in neuroblastoma. Cancers (Basel). 8:E132016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abualhasan MN, Good JA, Wittayanarakul K,
Anthony NG, Berretta G, Rath O, Kozielski F, Sutcliffe OB and
Mackay SP: Doing the methylene shuffle-Further insights into the
inhibition of mitotic kinesin Eg5 with S-trityl l-cysteine. Eur J
Med Chem. 54:483–498. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ye XS, Fan L, van Horn RD, Nakai R, Ohta
Y, Akinaga S, Murakata C, Yamashita Y, Yin T, Credille KM, et al: A
novel Eg5 Inhibitor (LY2523355) causes mitotic arrest and apoptosis
in cancer cells and shows potent antitumor activity in xenograft
tumor models. Mol Cancer Ther. 14:2463–2472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Johnson K, Moriarty C, Tania N, Ortman A,
DiPietrantonio K, Edens B, Eisenman J, Ok D, Krikorian S, Barragan
J, et al: Kif11 dependent cell cycle progression in radial glial
cells is required for proper neurogenesis in the zebrafish neural
tube. Dev Boil. 387:73–92. 2014. View Article : Google Scholar
|
|
28
|
Wiltshire C, Singh BL, Stockley J, Fleming
J, Doyle B, Barnetson R, Robson CN, Kozielski F and Leung HY:
Docetaxel-resistant prostate cancer cells remain sensitive to
S-trityl-l-cysteine-Mediated Eg5 inhibition. Mol Cancer Ther.
9:1730–1739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen C, Tian F, Lu L, Wang Y, Xiao Z, Yu C
and Yu X: Characterization of Cep85-a new antagonist of Nek2A that
is involved in the regulation of centrosome disjunction. J Cell
Sci. 128:3290–3303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bruinsma W, Aprelia M, Kool J, Macurek L,
Lindqvist A and Medema RH: Spatial separation of Plk1
phosphorylation and activity. Front Oncol. 5:1322015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Smith E, Hégarat N, Vesely C, Roseboom I,
Larch C, Streicher H, Straatman K, Flynn H, Skehel M, Hirota T, et
al: Differential control of Eg5-dependent centrosome separation by
Plk1 and Cdk1. EMBO J. 30:2233–2245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cahu J, Olichon A, Hentrich C, Schek H,
Drinjakovic J, Zhang C, Doherty-Kirby A, Lajoie G and Surrey T:
Phosphorylation by Cdk1 increases the binding of Eg5 to
microtubules in vitro and in Xenopus egg extract spindles. PLoS
One. 3:e39362008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baas PW and Matamoros AJ: Inhibition of
kinesin-5 improves regeneration of injured axons by a novel
microtubule-based mechanism. Neural Regen Res. 10:8452015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ou XH, Li S, Xu BZ, Wang ZB, Quan S, Li M,
Zhang QH, Ouyang YC, Schatten H, Xing FQ and Sun QY: p38α MAPK is a
MTOC-associated protein regulating spindle assembly, spindle length
and accurate chromosome segregation during mouse oocyte meiotic
maturation. Cell Cycle. 9:4130–4143. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Srivastava V and Lee H: Synthesis and
bio-evaluation of novel quinolino-stilbene derivatives as potential
anticancer agents. Bioorg Med Chem. 23:7629–7640. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gavriilidis P, Giakoustidis A and
Giakoustidis D: Aurora kinases and potential medical applications
of Aurora kinase inhibitors: A review. J Clin Med Res. 7:7422015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marques S, Fonseca J, Silva PM and Bousbaa
H: Targeting the spindle assembly checkpoint for breast cancer
treatment. Curr Cancer Drug Targets. 15:272–281. 2015. View Article : Google Scholar : PubMed/NCBI
|
